APA aipamena

Liu, J. F., Barry, W. T., Birrer, M., Lee, J., Buckanovich, R. J., Fleming, G. F., . . . Matulonis, U. A. (2014). A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer. Lancet Oncol.

Chicago Style aipamena

Liu, Joyce F., et al. "A Randomized Phase 2 Study of Combination Cediranib and Olaparib Versus Olaparib Alone As Recurrence Therapy in Platinum-sensitive Ovarian Cancer." Lancet Oncol 2014.

MLA aipamena

Liu, Joyce F., et al. "A Randomized Phase 2 Study of Combination Cediranib and Olaparib Versus Olaparib Alone As Recurrence Therapy in Platinum-sensitive Ovarian Cancer." Lancet Oncol 2014.